Aileron Therapeutics Inc (ALRN)

• $3.58

  $3.67

  $3.66
  

  2.19%

  Downside

  Day's Volatility :2.45%

  Upside

  0.27%

  
• $1.01

  $7.42

  $3.66
  

  72.4%

  Downside

  52 Weeks Volatility :86.39%

  Upside

  50.67%

  

Returns

What analysts predicted

Upside of 255.19%

• University Of Texas Investment Mgmt Co

  8.21%

• Nantahala Capital Management, LLC

  4.29%

• Alyeska Investment Group, L.P.

  2.49%

• Vanguard Group Inc

  2.34%

• Cable Car Capital LLC

  1.94%

• Prosight Management, LP

  1.22%

aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig